RU2664462C9 - Комбинированная терапия с помощью антитела к CD19 и аналога пурина - Google Patents

Комбинированная терапия с помощью антитела к CD19 и аналога пурина Download PDF

Info

Publication number
RU2664462C9
RU2664462C9 RU2014103490A RU2014103490A RU2664462C9 RU 2664462 C9 RU2664462 C9 RU 2664462C9 RU 2014103490 A RU2014103490 A RU 2014103490A RU 2014103490 A RU2014103490 A RU 2014103490A RU 2664462 C9 RU2664462 C9 RU 2664462C9
Authority
RU
Russia
Prior art keywords
lymphoma
seq
sequence
fludarabine
antibody
Prior art date
Application number
RU2014103490A
Other languages
English (en)
Russian (ru)
Other versions
RU2664462C2 (ru
RU2014103490A (ru
Inventor
Ютта АМЕРСДОРФЕР
Штефан Штайдль
Марк ВИНДЕРЛИХ
Сузанне КРОН
Лиза РОЙКЬЕР
Original Assignee
МорфоСис АГ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by МорфоСис АГ filed Critical МорфоСис АГ
Publication of RU2014103490A publication Critical patent/RU2014103490A/ru
Publication of RU2664462C2 publication Critical patent/RU2664462C2/ru
Application granted granted Critical
Publication of RU2664462C9 publication Critical patent/RU2664462C9/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
RU2014103490A 2011-08-16 2012-08-14 Комбинированная терапия с помощью антитела к CD19 и аналога пурина RU2664462C9 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161523862P 2011-08-16 2011-08-16
EP11177660.5 2011-08-16
EP11177660 2011-08-16
US61/523,862 2011-08-16
PCT/EP2012/065904 WO2013024095A1 (en) 2011-08-16 2012-08-14 Combination therapy with an anti - cd19 antibody and a purine analog

Publications (3)

Publication Number Publication Date
RU2014103490A RU2014103490A (ru) 2015-09-27
RU2664462C2 RU2664462C2 (ru) 2018-08-17
RU2664462C9 true RU2664462C9 (ru) 2018-09-28

Family

ID=47714800

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014103490A RU2664462C9 (ru) 2011-08-16 2012-08-14 Комбинированная терапия с помощью антитела к CD19 и аналога пурина

Country Status (25)

Country Link
US (3) US20140227277A1 (enExample)
EP (2) EP2744826B1 (enExample)
JP (1) JP6114273B2 (enExample)
KR (3) KR102117202B1 (enExample)
CN (1) CN103703027B (enExample)
AU (1) AU2012296905B2 (enExample)
BR (1) BR112013033916B1 (enExample)
CA (1) CA2841738C (enExample)
CY (1) CY1125148T1 (enExample)
DK (1) DK2744826T3 (enExample)
ES (1) ES2909720T3 (enExample)
HR (1) HRP20220224T1 (enExample)
HU (1) HUE058855T2 (enExample)
IL (1) IL230295B (enExample)
LT (1) LT2744826T (enExample)
MX (1) MX353589B (enExample)
PL (1) PL2744826T3 (enExample)
PT (1) PT2744826T (enExample)
RS (1) RS63121B1 (enExample)
RU (1) RU2664462C9 (enExample)
SG (1) SG10201606788VA (enExample)
SI (1) SI2744826T1 (enExample)
SM (1) SMT202200160T1 (enExample)
WO (1) WO2013024095A1 (enExample)
ZA (1) ZA201401835B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2514591A (en) * 2013-05-30 2014-12-03 Mologen Ag Predictive biomarker for cancer therapy
ES2523901B1 (es) * 2013-05-31 2015-12-02 Universidad Autónoma de Madrid Uso de la deguelina como terapia suplementaria de la leucemia linfoide crónica
AU2015277516A1 (en) * 2014-06-16 2016-12-22 Xencor, Inc. Treatment for chronic lymphocytic leukemia (CLL)
IL249533A0 (en) * 2014-06-16 2017-02-28 Xencor Inc Treatment of chronic lymphocytic leukemia
PL3302550T3 (pl) * 2015-05-26 2020-02-28 Morphosys Ag Kombinacja przeciwciała anty-cd19 i inhibitora kinazy tyrozynowej brutona i jej zastosowania
SI3337506T1 (sl) 2015-08-21 2021-12-31 Morphosys Ag Kombinacije in njihove uporabe
SG11201810159TA (en) * 2016-05-30 2018-12-28 Morphosys Ag Methods for predicting therapeutic benefit of anti-cd19 therapy in patients
IL266216B2 (en) 2016-10-28 2023-09-01 Morphosys Ag Combination of anti-cd19 antibody with bcl-2 inhibitor and uses thereof
IL270855B2 (en) 2017-05-31 2023-03-01 Morphosys Ag A therapeutic paradigm for anti-cd19 anti-CD19 antibody combination therapy and Ventoclax
JP7279011B2 (ja) 2017-07-10 2023-05-22 インターナショナル－ドラッグ－ディベロップメント－バイオテック 抗ｃｄ２０抗体または化学療法薬と併用して非フコシル化アポトーシス促進性抗ｃｄ１９抗体を用いるｂ細胞悪性の治療
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
WO2020150513A1 (en) * 2019-01-17 2020-07-23 Fred Hutchinson Cancer Research Center Methods to enhance the selectivity and effectiveness of cancer treatments
IL313736A (en) * 2021-12-22 2024-08-01 Incyte Corp Treatment paradigm for CD19 antibody therapy
AU2024296212A1 (en) 2023-07-13 2026-01-22 Christian-Albrechts-Universität Zu Kiel Humanized anti-cd7 antibody

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA004107B1 (ru) * 1998-08-11 2003-12-25 Айдек Фармацевтикалс Корпорэйшн Комбинированная терапия в-клеточных лимфом, предусматривающая введение антитела против cd20
US20100272723A1 (en) * 2006-08-14 2010-10-28 Xencor, Inc. Optimized Antibodies that Target CD19
US20110165152A1 (en) * 2009-08-14 2011-07-07 Martin Dreyling Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11852A (en) 1854-10-31 Abraham bassford
US106A (en) 1915-08-24 Specipication
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
EP1194167B1 (en) 1999-06-09 2009-08-19 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
US20020058029A1 (en) 2000-09-18 2002-05-16 Nabil Hanna Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory antibody combination
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
EP2216342B1 (en) 2003-07-31 2015-04-22 Immunomedics, Inc. Anti-CD19 antibodies
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
US8444973B2 (en) 2005-02-15 2013-05-21 Duke University Anti-CD19 antibodies and uses in B cell disorders
AU2006262232A1 (en) 2005-06-20 2007-01-04 Medarex, Inc. CD19 antibodies and their uses
WO2007064911A1 (en) * 2005-12-02 2007-06-07 Biogen Idec Inc. Anti-mouse cd20 antibodies and uses thereof
CA2635623C (en) 2005-12-30 2015-02-17 Michael Super Anti-cd19 antibodies with reduced immunogenicity
AU2007294575B2 (en) 2006-09-08 2013-06-27 Viela Bio, Inc. Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
DK2176298T3 (en) 2007-05-30 2018-02-12 Xencor Inc Methods and compositions for inhibiting CD32B-expressing cells
DK2211904T3 (en) 2007-10-19 2016-10-24 Seattle Genetics Inc Cd19-binding agents and uses thereof
SG173654A1 (en) 2009-02-23 2011-09-29 Glenmark Pharmaceuticals Sa Humanized antibodies that bind to cd19 and their uses
CA2765080C (en) 2009-06-24 2018-07-17 The Feinstein Institute For Medical Research Methods for treating chronic lymphocytic leukemia
TWI409079B (zh) * 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
MX2012005163A (es) * 2009-11-06 2012-11-22 Infinity Pharmaceuticals Inc Formulaciones orales de un inhibidor de la ruta de hedgehog.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA004107B1 (ru) * 1998-08-11 2003-12-25 Айдек Фармацевтикалс Корпорэйшн Комбинированная терапия в-клеточных лимфом, предусматривающая введение антитела против cd20
US20100272723A1 (en) * 2006-08-14 2010-10-28 Xencor, Inc. Optimized Antibodies that Target CD19
US20110165152A1 (en) * 2009-08-14 2011-07-07 Martin Dreyling Combination therapy of an afucosylated cd20 antibody with fludarabine and/or mitoxantrone

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HORTON H.M. et al., Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia, Cancer Research, 2008, Vol.68, N. 19, pp.8049-8057. *

Also Published As

Publication number Publication date
PT2744826T (pt) 2022-05-19
NZ617771A (en) 2016-01-29
CA2841738A1 (en) 2013-02-21
RU2664462C2 (ru) 2018-08-17
MX353589B (es) 2018-01-19
JP6114273B2 (ja) 2017-04-12
EP4083071A3 (en) 2023-02-22
HUE058855T2 (hu) 2022-09-28
KR20140071368A (ko) 2014-06-11
CN103703027A (zh) 2014-04-02
ZA201401835B (en) 2015-06-24
US20140227277A1 (en) 2014-08-14
ES2909720T3 (es) 2022-05-10
BR112013033916B1 (pt) 2022-11-16
LT2744826T (lt) 2022-04-25
RU2014103490A (ru) 2015-09-27
CN103703027B (zh) 2018-01-12
IL230295B (en) 2018-03-29
EP2744826A1 (en) 2014-06-25
MX2013014935A (es) 2014-07-09
SG10201606788VA (en) 2016-09-29
HRP20220224T1 (hr) 2022-04-29
CA2841738C (en) 2022-12-06
BR112013033916A2 (pt) 2017-11-28
RS63121B1 (sr) 2022-05-31
US20240424012A1 (en) 2024-12-26
KR102117202B1 (ko) 2020-06-01
SMT202200160T1 (it) 2022-05-12
WO2013024095A1 (en) 2013-02-21
AU2012296905B2 (en) 2017-01-05
SI2744826T1 (sl) 2022-05-31
KR20200060779A (ko) 2020-06-01
DK2744826T3 (da) 2022-03-28
JP2014525925A (ja) 2014-10-02
PL2744826T3 (pl) 2022-05-30
US20200352975A1 (en) 2020-11-12
EP2744826B1 (en) 2022-02-09
KR20190094478A (ko) 2019-08-13
CY1125148T1 (el) 2024-12-13
EP4083071A2 (en) 2022-11-02

Similar Documents

Publication Publication Date Title
RU2664462C9 (ru) Комбинированная терапия с помощью антитела к CD19 и аналога пурина
US20240009196A1 (en) Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
US12194095B2 (en) Combinations and uses thereof
RU2625222C2 (ru) Комбинированная терапия антителом к cd19 и азотистым ипритом
AU2012296905A1 (en) Combination therapy with an anti - CD19 antibody and a purine analog
JP2014525925A5 (enExample)
HK40081594A (en) Combination therapy with an anti-cd19 antibody and a nitrogen mustard
HK40069168A (en) Combinations and uses thereof
HK40023127A (en) Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof
HK1195322A (en) Combination therapy with an anti-cd19 antibody and a purine analog
NZ617771B2 (en) Combination therapy with an anti - cd19 antibody and a purine analog
HK1195322B (en) Combination therapy with an anti-cd19 antibody and a purine analog

Legal Events

Date Code Title Description
TH4A Reissue of patent specification